inclusion criteria: age ≥ 18 years and ≤ 75 years at the time of the assessment able and willing to understand the study, adhere to all study procedures, and provide written informed consent diagnosis of covid-19 disease: if symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours from swab to the time of commencing informed consent: if asymptomatic, initial diagnosis of sars-cov-2 infection with positive fda-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent

inclusion criteria: age ≥ 18 years and ≤ 75 years at the time of the assessment able and willing to understand the study, adhere to all study procedures, and provide written informed consent diagnosis of covid-19 disease: if symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours from swab to the time of commencing informed consent: if asymptomatic, initial diagnosis of sars-cov-2 infection with positive fda-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent

inclusion criteria: 1. age ≥ 18 years and ≤ 75 years at the time of the assessment 2. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 3. diagnosis of covid-19 disease: 1. if symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours from swab to the time of commencing informed consent: 2. if asymptomatic, initial diagnosis of sars-cov-2 infection with positive fda-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent

inclusion criteria: 1. age ≥ 18 years and ≤ 75 years at the time of the assessment 2. able and willing to understand the study, adhere to all study procedures, and provide written informed consent 3. diagnosis of covid-19 disease: 1. if symptomatic, the presence of mild to moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours from swab to the time of commencing informed consent: 2. if asymptomatic, initial diagnosis of sars-cov-2 infection with positive fda-cleared molecular diagnostic assay obtained no more than 72 hours from initial swab to the time of commencing informed consent